ATE118172T1 - Zusammensetzung und verfahren für die behandlung von osteoporose bei säugetieren. - Google Patents

Zusammensetzung und verfahren für die behandlung von osteoporose bei säugetieren.

Info

Publication number
ATE118172T1
ATE118172T1 AT90811032T AT90811032T ATE118172T1 AT E118172 T1 ATE118172 T1 AT E118172T1 AT 90811032 T AT90811032 T AT 90811032T AT 90811032 T AT90811032 T AT 90811032T AT E118172 T1 ATE118172 T1 AT E118172T1
Authority
AT
Austria
Prior art keywords
osteoporosis
mammals
treatment
composition
igf
Prior art date
Application number
AT90811032T
Other languages
English (en)
Inventor
Robert R Dr Buerk
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE118172T1 publication Critical patent/ATE118172T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT90811032T 1990-01-03 1990-12-27 Zusammensetzung und verfahren für die behandlung von osteoporose bei säugetieren. ATE118172T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46041690A 1990-01-03 1990-01-03

Publications (1)

Publication Number Publication Date
ATE118172T1 true ATE118172T1 (de) 1995-02-15

Family

ID=23828617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90811032T ATE118172T1 (de) 1990-01-03 1990-12-27 Zusammensetzung und verfahren für die behandlung von osteoporose bei säugetieren.

Country Status (15)

Country Link
US (2) US5646116A (de)
EP (1) EP0436469B1 (de)
JP (1) JP3053116B2 (de)
KR (1) KR100200995B1 (de)
AT (1) ATE118172T1 (de)
AU (1) AU629443B2 (de)
CA (1) CA2033469C (de)
DE (1) DE69016768T2 (de)
DK (1) DK0436469T3 (de)
ES (1) ES2067720T3 (de)
GR (1) GR3015490T3 (de)
IE (1) IE66240B1 (de)
IL (1) IL96841A (de)
NZ (1) NZ236618A (de)
ZA (1) ZA916B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222117T1 (de) * 1990-05-30 2002-08-15 Harvard College Kombination aus igf-i und tgf-beta zur knochenregenerierung
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
EP0642350A4 (de) * 1993-01-25 1995-06-28 Beth Israel Hospital Methode zur modifizierung, diagnose und dem aufspüren von igf-1 sensitiven zellbarriereeigenschaften.
AU713275B2 (en) * 1994-07-20 1999-11-25 Celtrix Pharmaceuticals, Inc. IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1996007744A1 (en) * 1994-09-08 1996-03-14 Chiron Corporation A method of improved production of insulin-like growth factor
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US7026292B1 (en) 1995-12-12 2006-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
HUP9904049A3 (en) * 1996-05-31 2000-07-28 Novo Nordisk As Growth hormone component and bone anti-resorptive agent in cyclic(coherence)treatment of osteoporosis
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
US6846496B1 (en) 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
ES2266187T3 (es) 2000-03-24 2007-03-01 Genentech, Inc. Uso de la insulina para el tratamiento de trastornos del cartilago.
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US7189233B2 (en) * 2001-10-22 2007-03-13 Surgrx, Inc. Electrosurgical instrument
WO2005002590A1 (ja) * 2003-07-01 2005-01-13 Astellas Pharma Inc. 骨量増加誘導剤
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20050171015A1 (en) * 2003-10-31 2005-08-04 Crabtree Gerald R. Methods and agents for enhancing bone formation or preventing bone loss
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
WO2014143992A1 (en) * 2013-03-15 2014-09-18 University Of Rochester Treating lysosomal storage disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486491T2 (de) * 1983-04-25 2003-01-16 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
DE3851776T2 (de) * 1987-04-28 1995-05-04 Boehringer Mannheim Gmbh Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
IL88344A (en) * 1987-11-12 1994-06-24 Schering Corp Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages

Also Published As

Publication number Publication date
CA2033469A1 (en) 1991-07-04
KR100200995B1 (ko) 1999-06-15
IL96841A0 (en) 1991-09-16
IE910004A1 (en) 1991-07-17
AU629443B2 (en) 1992-10-01
EP0436469B1 (de) 1995-02-08
NZ236618A (en) 1997-06-24
CA2033469C (en) 2003-01-28
ZA916B (en) 1991-08-28
US5646116A (en) 1997-07-08
GR3015490T3 (en) 1995-06-30
IE66240B1 (en) 1995-12-13
EP0436469A1 (de) 1991-07-10
KR910021243A (ko) 1991-12-20
DE69016768T2 (de) 1995-06-14
ES2067720T3 (es) 1995-04-01
DK0436469T3 (da) 1995-04-03
AU6853290A (en) 1991-07-04
DE69016768D1 (de) 1995-03-23
US6174857B1 (en) 2001-01-16
JP3053116B2 (ja) 2000-06-19
JPH04235135A (ja) 1992-08-24
IL96841A (en) 1996-05-14

Similar Documents

Publication Publication Date Title
DE69016768D1 (de) Zusammensetzung und Verfahren für die Behandlung von Osteoporose bei Säugetieren.
ATE187889T1 (de) Vorbeugung und behandlung der peripheren neuropathie
DE69331469T2 (de) Verfahren zur behandlung von abfällen
DE3677400D1 (de) Verfahren zur behandlung von knochenersatz-implantaten.
ATE324866T1 (de) Verfahren zur behandlung von gefässrestenose durch inhalieren von stickoxid
DE69415100D1 (de) Vliesstoffgegenstand zur Behandlung von Oberflächen, Verfahren zur Herstellung und Verwendung davon
ATE192017T1 (de) Verfahren zur erzeugung von pflanzenembryoiden mit austrocknungstoleranz und verfahren zur keimung von embryoiden mit austrocknungstoleranz
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
DE69129115D1 (de) Neues verfahren zur behandlung von depression
DE69227696T2 (de) Zusammensetzungen zur behandlung von hiv-infektionen
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
DE69018799D1 (de) IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
DE69303527D1 (de) Verfahren zur Behandlung von kleinen Löchern in Substratmaterial
ATE145193T1 (de) Verfahren zur bakteriellen behandlung von mit flora verschmutzten kreisläufen der papierindustrie
ATE178206T1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69330172T2 (de) Zusammensetzung für die Behandlung von Fasern, damit behandelte Fasern, und Verfahren zur Behandlung von Fasern mit dieser Zusammensetzung
DE58902128D1 (de) Verfahren zur behandlung von klaerschlamm.
DE59308384D1 (de) Verfahren zur Behandlung von Gülle
DE59103291D1 (de) Verfahren zur bekämpfung von samen- und/oder bodenbürtigen schaderregern durch saatgutbehandlung.
DE69119718D1 (de) Verfahren und Zusammensetzung zur Behandlung von Textilien
DE69124035D1 (de) Anordnungen mit Quanten-Interferenz-Effekt und Verfahren zur Behandlung von Interferenz-Strom
DE69214139D1 (de) Verfahren zur behandlung von mit feuchtigkeit enthaltenden feinkohlen
DE68916805D1 (de) Verfahren zur herstellung von tocopherolen.
DE68907914D1 (de) Verfahren zur behandlung von brandwunden.
ATA171489A (de) Verfahren zur behandlung von abfallstoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee